AcelRx Pharmaceuticals Inc (ACRX.O)

ACRX.O on Consolidated Issue listed on NASDAQ Global Market

9 Feb 2016
Change (% chg)

$0.11 (+3.27%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ACRX.O


AcelRx Pharmaceuticals, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. The Company's lead product candidate, Zalviso, is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso... (more)


Beta: 2.27
Market Cap(Mil.): $149.34
Shares Outstanding(Mil.): 44.45
Dividend: --
Yield (%): --


  ACRX.O Industry Sector
P/E (TTM): -- 36.59 38.48
EPS (TTM): -0.63 -- --
ROI: -26.38 6.96 14.34
ROE: -55.88 9.03 15.17
Search Stocks

UPDATE 1-AcelRx Pharma's pain drug succeeds in late-stage study

Sept 9 AcelRx Pharmaceuticals Inc said its experimental pain drug for patients undergoing abdominal surgery met the main goal in a late-stage study.

09 Sep 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : Pechala's Reports
Provider : Reuters Investment Profile
Provider : Ford Investor Services, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks